First in Human Study in Subjects With Obesity, But Otherwise Healthy
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
Full description
This is a Phase 1, randomized, placebo-controlled, double-blind, sequential parallel group study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
Willing and able to provide informed consent prior to initiation of any study specific procedures/activities.
-
Males and females ≥18 to <=65 years of age, at the time of signing informed consent, who have been diagnosed with obesity, or have signs/symptoms consistent with obesity.
-
Except for obesity, otherwise healthy as determined by the investigator based on a medical evaluation including physical exam, medical history, laboratory tests, and ECGs.
-
Body mass index (BMI) ≥ 30 kg/m2 to 45 kg/m2 (Obesity to be confirmed by Caliper test).
-
Has maintained a stable body weight during the 3 months prior to Screening (<5% body weight change).
-
Willing to maintain current diet and physical activity regimen.
- SAD Cohorts (Be willing to eat a standard diet while in the Clinical Research Unit).
- MAD Cohorts (Be willing to eat a standard diet while in the Clinical Research Unit). If appetite decreases, participants may not maintain their current diet.
-
Females must be of non-reproductive potential:
-
Postmenopausal defined as:
- Age of ≥55 years with no menses for at least 12 months; OR
- Age <55 years with no menses for at least 12 months AND with a follicle-stimulating hormone level >40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR
-
History of hysterectomy; OR
-
History of bilateral oophorectomy
-
History of tubal ligation (surgically sterile)
-
-
Males must agree to practice an acceptable method of effective birth control while on study through 5 half-lives plus one week after receiving last dose of DA-1726.
Acceptable methods of birth control include:
- Sexual abstinence
- Vasectomy and testing that shows there are no sperm in semen.
- Condom with spermicide (male) in combination with barrier methods (diaphragm, cervical cap, or cervical sponge), hormonal birth control, or IUS (females)
Exclusion criteria
-
History or clinical evidence of diabetes mellitus, including a fasting glucose of ≥ 120 mg/dL and/or HbA1c ≥ 6.5% at Screening.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
-
History of cholecystectomy < 6 months prior to screening.
-
Subjects with screening calcitonin level of ≥15 pg/mL (calcitonin levels will be monitored during the study).
-
Triglycerides ≥500 mg/dL at Screening.
-
History of pancreatitis.
-
Have a medical history or current evidence of clinically significant cardiac condition as evidenced by any of the following at Screening :
- QTc at Screening from locally generated data of >450 msec in males or >470 msec in females or history of long QT syndrome
- Supine systolic BP higher than 150 mmHg and a supine diastolic BP higher than 95 mmHg at Screening or check-in
- Supine HR of <50 or >100 beats per minute on 2 of 3 triplicate ECGs at Screening or check-in
- Heart block of the 1st, 2nd, or 3rd degree
- Sick sinus syndrome (irregular heartbeat patterns)
- Disorders in cardiac conduction
- Peripheral blood circulation issues
- Heart valve conditions
- Cardiomyopathy
- History of myocardial infarction
- Unstable angina
- History of heart artery bypass surgery
- History of stroke
- History of heart failure
-
Regular consumption of caffeine-containing beverages, including coffee, tea, energy drinks, and caffeinated sodas, exceeding 3 cups per day.
-
Current use of tobacco products or having a history of tobacco use within the past 6 months.
-
Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data.
-
History of GI abnormality that could affect GI motility (including small bowel or colonic resection, inflammatory bowel disease, irritable bowel syndrome, gastroparesis [clinically significant gastric emptying abnormality], and colon / GI tract cancer).
-
Have a history of chronic medical conditions involving the heart, liver, or kidneys (e.g., atherosclerotic coronary vascular disease (ASCVD), heart failure, liver cirrhosis, chronic kidney disease).
-
Untreated or uncontrolled hypo/hyperthyroidism defined as thyroid-stimulating hormone >6 mIU/L or <0.4 mIU/L.
-
Obesity that was induced by other endocrinologic disorders (e.g., Cushing's Syndrome).
-
Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies.
-
Evidence of hepatitis C and/or positive hepatitis C antibody and hepatitis B, hepatitis B core antibody, and/or positive hepatitis B surface antigen.
-
Have a history or presence of psychiatric disorders that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
-
Any lifetime history of a suicidal attempt or any suicidal behavior, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).
-
History of malignancy of any type, other than basal cell carcinoma, occurring less than 5 years prior to randomization.
-
History of substance abuse (i.e., alcohol or illicit substances) within 12 months prior to Screening; and/or a positive test for alcohol/drugs of abuse at Screening.
-
Previous surgical treatment for obesity or any form of bariatric surgery.
-
Currently receiving treatment in another investigational drug or device study or 5 half lives or 30 days since last dose of investigational drug, whichever is longer.
-
Participants with a history of significant allergic or drug reactions (NSAIDs or antibiotics) or known allergy to DA 1726 excipients that would place them at increased risk.
-
Have received any vaccine ≤30 days prior to check-in.
-
Albumin level <3.5 g/dL (<35 g/L) at Screening.
-
Aspartate aminotransferase (AST) ≥1.25 × upper limit of normal (ULN) at Screening.
-
Alanine aminotransferase (ALT) ≥1.25 × upper limit of normal (ULN) at Screening.
-
Bilirubin >1.25 upper limit of normal (ULN) at Screening.
-
Absolute neutrophil count <lower limit of normal (LLN) at Screening.
-
Estimated glomerular filtration rate of ≤60 mL/min for women and men (based on the Chronic Kidney Disease Epidemiology Collaboration equation) at the Screening.
-
Fasting low-density lipoprotein ≥160 mg/dL at Screening.
-
Hemoglobin <LLN at Screening.
-
Platelet count <LLN at Screening.
-
Current or history of treatment with medications that may cause significant weight gain, within 3 months of Screening, including:
- Systemic corticosteroids (except for a short course of treatment, i.e., 7-10 days)
- Tricyclic antidepressants
- Atypical antipsychotics
- Mood stabilizers (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium)
- Antidiabetic Medications (e.g., insulin or certain sulfonylureas, that may lead to weight gain)
- Beta-blockers (e.g., the ones used to treat conditions like hypertension that may cause weight gain)
- Antihistamines (particularly the first-generation ones, that may have sedative effects and could potentially contribute to weight gain)
- Contraceptives
- Any non-steroidal anti-inflammatory drugs
-
Current participation (or within the last 3 months) in an organized weight reduction program or currently using or has used within 3 months prior to Screening: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phentermine, naltrexone, lorcaserin, liraglutide, semaglutide, tirzepatide or metformin.
Trial design
Primary purpose
Allocation
Interventional model
Masking
81 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Ji Eun Lee, PharmD; Robert Homolka, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal